Mike is an immunologist with >25yrs of experience spanning numerous biotechs including Jounce and LeukoSite (acquired), where his work led to the development and subsequent approval of Vedolizumab (Entyvio®). Mike joined in 2020 as a founding member of the team.

• 

  Chief Scientific Officer (CSO) in Phenomic AI

  Targeting Tumor Biology